Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model - Wikidata - awgldk - TriplyDB

Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model

Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model

http://www.wikidata.org/entity/Q34663623

about

Rett Syndrome: Crossing the Threshold to Clinical Translation Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Rett Syndrome: Reaching for Clinical Trials A novel use of gentamicin in the ROS-mediated sensitization of NCI-H460 lung cancer cells to various anticancer agents Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies.Preclinical research in Rett syndrome: setting the foundation for translational success.Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor Respiratory phenotypes are distinctly affected in mice with common Rett syndrome mutations MeCP2 T158A and R168X.New trends in aminoglycosides use.Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations Nonsense-mediated decay in genetic disease: friend or foe?Characterization of the MeCP2R168X knockin mouse model for Rett syndrome.Complexities of Rett syndrome and MeCP2 Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.Rescue of Methyl-CpG Binding Protein 2 Dysfunction-induced Defects in Newborn Neurons by Pentobarbital.The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.Suppression of premature termination codons as a therapeutic approach.A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies Wild-type microglia do not reverse pathology in mouse models of Rett syndrome A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome Development of generic immunoassay for the detection of a series of aminoglycosides with 6'-OH group for the treatment of genetic diseases in biological samples.A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides Neuronal morphology in MeCP2 mouse models is intrinsically variable and depends on age, cell type, and Mecp2 mutation.Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives.Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options Rescue of behavioral and EEG deficits in male and female Mecp2-deficient mice by delayed Mecp2 gene reactivation.Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.Therapeutics based on stop codon readthrough.Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.Translational research: Rett syndrome and tuberous sclerosis complex.Rett syndrome and MeCP2.Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes.When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.Defects in brainstem neurons associated with breathing and motor function in the Mecp2R168X/Y mouse model of Rett syndrome.

P2860

Q26772909-B64B67DF-9E84-4DBC-A47A-5CABA445EFCF Q27023257-34E689C2-2783-40DB-AE24-7B303685FCB8 Q27337778-FC9CC90C-C4A4-416A-B80E-F402221CEC1D Q28393238-21C7A80B-E57A-4F08-9617-647F5F4DE660 Q28743688-993C5EB0-99DF-425D-BBE6-BE3E34751066 Q30445073-AC790192-C834-4411-9200-A896FD9236F9 Q30527828-D8DFA0FC-0AB5-4E0E-9BC4-AF761D37C921 Q30650123-E9D5565A-0757-4779-84A8-74F56CB70648 Q33799538-D2806DA4-88BE-4259-9768-24EB57A940EA Q33799590-2C232FCC-C499-4DFD-A21C-85247AD738A9 Q33901030-905F35D9-9B6D-49B9-B5B9-2FCBCB65F782 Q33951177-E7349899-7D03-47DD-B476-101F2545566E Q34475657-419F2F77-F371-430D-A9B3-4A05436C9A8D Q34658988-6050628D-2207-4C18-A488-E1FE94FEE429 Q34776273-2EC066FC-781C-45DA-A650-7C0DF7E92A4E Q35080184-A9FF8B0B-5FBB-4911-AC46-44EE0B694FEA Q35253188-065B1C32-CFFD-4AAE-8C36-30CCC3518572 Q35287888-0FF77F28-9FE3-4DFF-A21E-7463003DE790 Q35502009-0C42E9AA-F286-404A-B6B5-790D36244E53 Q35661233-640F8A7A-4D65-462E-BBE9-B10F7D43FFD4 Q36203719-15D4A92C-BBB0-43DD-A214-C1A7D57879E2 Q36214442-3BAECB7E-385D-494A-9690-CF5377A0F003 Q36386922-27EF5ECE-8695-4220-A13A-2F7701985510 Q36389318-23EAAB1E-FDDA-409B-BC67-22299843BB09 Q36514633-BB79A26C-EFCB-41CB-A23B-43E569451A6A Q36533566-98B4BFDA-1BF1-4472-9EEF-D1CA2AFA0B04 Q36726249-241F072E-D603-4A87-B649-F4E1338607B1 Q37107272-4033F5A4-2D7B-4B66-82FF-587AF8C79F6B Q37213531-2E439389-43DE-467B-9BB7-869F8030AE06 Q37383972-DE3D4418-CAC4-44BC-9D09-C5A1EFECA394 Q37406408-0A408F98-1B3F-4DF8-82DD-EC681508648D Q37511774-1697D9BE-3371-42CA-95FE-DD78F3176A47 Q37638359-8612B517-47FE-434C-B0B5-5354D9408EB9 Q37726532-7CF441D7-6D7C-43FD-9CA3-856629D65597 Q37942280-3D80ABA7-8E5E-43F7-9961-A136F001F470 Q38194967-FB5D16B4-06B9-44A2-8A0C-B303A152B76E Q38737126-1870E6C3-5C7B-445E-B7A9-594A6884B469 Q39689317-334042DD-9F6E-44A2-B29E-75654808B82A Q42142778-0F2499B8-79D5-43C9-9F6B-466F1E791933 Q46370352-56881C62-2974-4B69-BEF8-2AFB2A7F4B7C

P2860

Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model

http://www.wikidata.org/entity/Q34663623

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Readthrough of nonsense mutati ...... eneration of a new mouse model

@ast

Readthrough of nonsense mutati ...... eneration of a new mouse model

@en

Readthrough of nonsense mutati ...... eneration of a new mouse model

@nl

type

label

Readthrough of nonsense mutati ...... eneration of a new mouse model

@ast

Readthrough of nonsense mutati ...... eneration of a new mouse model

@en

Readthrough of nonsense mutati ...... eneration of a new mouse model

@nl

prefLabel

Readthrough of nonsense mutati ...... eneration of a new mouse model

@ast

Readthrough of nonsense mutati ...... eneration of a new mouse model

@en

Readthrough of nonsense mutati ...... eneration of a new mouse model

@nl

P1433

Q34663623-C8A97812-F656-4555-BA14-DF7AF9108982

P1476

Q34663623-5C31415E-F3A1-49EB-8D7D-E6531C5AA2F5

P2093

Q34663623-010519DB-06E7-4A65-8B8C-EEDFF7048A07

Q34663623-222AC4B5-C198-4363-ABA4-4761EAF74191

Q34663623-59C52ACC-B35B-4B80-ADDD-BA5A13AF0A31

Q34663623-61C6D8E0-4F8F-4AE6-8FD4-E9285A63040A

Q34663623-827A6ADF-D3E5-4706-91CA-53221C54C614

Q34663623-F6B368A7-AC92-44AF-ACDC-51ABB399751E

P2860

Q34663623-01E9E580-C9F5-4915-890F-72647FA65309

Q34663623-0637BC5D-BFFA-4E0F-BD66-3B5658DC3112

Q34663623-1AF93A9A-D4FB-4FA5-B767-6F99AB6791DC

Q34663623-228D7F45-4F12-4A5D-8F05-E05571048B14

Q34663623-398FA966-019E-49B9-95F9-ACB84F34F851

Q34663623-494FA6F3-0738-4479-82F0-2E45EEF0E515

Q34663623-5BC3C52A-A463-4D37-9212-92F2DE713E07

Q34663623-66159AC1-18AC-4584-AED9-DBA9E40AEDF9

Q34663623-6F71F52F-E300-4306-B712-DFE9ED474AD9

Q34663623-72D16AC8-024B-49A2-9719-4B6347EF01A0

P2888

Q34663623-B54A56B2-EDB9-437A-B819-27B776C70375

P304

Q34663623-A258EF50-3149-4F74-A628-A1054F71817B

P31

Q34663623-E8B3B96C-791D-430D-AEEE-D3390E06BD20

P356

Q34663623-919D38A7-FD4E-4043-9316-8A3A0C9B6844

P433

Q34663623-5EE7D8EF-250A-4921-8A16-7901ED4398FD

P478

Q34663623-F1539FD4-D0C7-4662-AE0A-8C1B25A30924

P50

Q34663623-25D26705-0B8B-4B12-BD55-CF968A57B968

Q34663623-B3515DA0-2483-449C-9D04-13B2DDA14CD0

P577

Q34663623-2F6015B3-BE26-47D2-BC6F-E391265D0D4F

P5875

Q34663623-0371BFD3-92B5-40D4-AC6E-3CD3057380EC

P6179

Q34663623-70C3434F-5840-42F8-B7BD-6101F1C94695

P698

Q34663623-EBDAADC0-3EC3-49AD-8B52-2FE2FFAF9306

P932

Q34663623-0F19600E-2A49-40A6-82D4-795E1EBBA6C8

P356

S00109-010-0704-4

P1433

Journal of Molecular Medicine

P1476

Readthrough of nonsense mutati ...... eneration of a new mouse model

@en

P2093

Cornelia Brendel

http://www.w3.org/2001/XMLSchema#string

Igor Nudelman

http://www.w3.org/2001/XMLSchema#string

Jutta Gärtner

http://www.w3.org/2001/XMLSchema#string

Peter Huppke

http://www.w3.org/2001/XMLSchema#string

Timor Baasov

http://www.w3.org/2001/XMLSchema#string

Valery Belakhov

http://www.w3.org/2001/XMLSchema#string

P2860

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome

Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice

Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice

Reversal of neurological defects in a mouse model of Rett syndrome

Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3

Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice.

Aminoglycosides: nephrotoxicity

Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations

Aminoglycoside antibiotics.

P2888

s00109-010-0704-4

P304

389-398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00109-010-0704-4

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Jan Eike Wegener

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49647803

http://www.w3.org/2001/XMLSchema#string

P6179

1038025680

http://www.w3.org/2001/XMLSchema#string

P698

21120444

http://www.w3.org/2001/XMLSchema#string

P932

3055984

http://www.w3.org/2001/XMLSchema#string